← Back to patent-cliff list
64Cu-DOTA-AE105
Tier C — Watch / trade64Cu-DOTA-AE105
Rigshospitalet
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Radiopharmaceutical
Type
Targets：PLAUR
Indications (approved)：Prostate cancer, Bladder cancer, Breast cancer
Regional status
US
-
EU
Phase II
2024-06-01
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of 64Cu-DOTA-AE105?
Approved indications include: Prostate cancer, Bladder cancer, Breast cancer.
When does the 64Cu-DOTA-AE105 patent expire?
No public expiry year is available for 64Cu-DOTA-AE105 yet; this page updates once verified.
How do I get a quote for 64Cu-DOTA-AE105 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01